D. Boral Capital Reaffirms “Buy” Rating for OS Therapies (NYSE:OSTX)

OS Therapies (NYSE:OSTX)‘s stock had its “buy” rating reissued by equities researchers at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $20.00 price objective on the stock.

Separately, Maxim Group boosted their target price on shares of OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th.

OS Therapies Price Performance

NYSE OSTX opened at $1.84 on Thursday. The firm’s fifty day simple moving average is $3.42. OS Therapies has a 1 year low of $1.58 and a 1 year high of $7.00.

Insider Buying and Selling at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 16,720 shares of OS Therapies stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the transaction, the insider now owns 2,531,211 shares of the company’s stock, valued at approximately $17,060,362.14. The trade was a 0.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new position in shares of OS Therapies Inc (NYSE:OSTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.